Effectiveness and safety of the intradialytic oral nutrition over nutritional markers and intradialytic hypotension in comparison with home complementation in patients undergoing hemodialysis

n
data

Plain English summary of protocol

Background and study aims

Hemodialysis (HD) is a process of purifying the blood of a person whose kidneys are not working normally. HD causes an inflammatory effect which decreases the appetite, increases certain gastrointestinal (digestive system) symptoms and consequently the patients consume fewer nutrients, increasing the risk of developing protein energy wasting (reduced body protein and fat mass). This could be treated and even prevented with oral nutritional supplementation containing extra protein and calories. It's been suggested that oral supplementation during HD treatment, called intradialytic oral nutrition supplementation (ION), can improve survival. Despite the proposed benefits, health personnel see ION as a risk factor for many adverse events such as intradialytic hypotension (low blood pressure) and other gastrointestinal and adverse events like nausea, vomiting, diarrhea and infections. The prevalence of these events has been little studied, and health personnel in HD units should not base their decision not to give ION based on this limited evidence. Therefore, the aim of this study is to determine the safety of ION over intradialytic hypotension and its effectiveness over some clinical nutritional markers in comparison with standard supplementation (at home).

Who can participate?

Patients aged 18 to 65 who are receiving chronic (long-term) HD treatment

What does the study involve?

Participants are randomly allocated to one of two group. Both groups consume a liquid supplement containing extra protein and calories. The intervention group consume the supplement at minutes 60-75 and 210-225 of a HD session. The control group consume two portions of the supplement at home on a specific schedule on a non-HD day. The incidence of intradialytic hypotension is assessed during HD sessions.

What are the possible benefits and risks of participating?

This study may increase the limited general knowledge of the safety and effectiveness of ION, and may increase health personnel's confidence for giving supplements during HD treatment and therefore prevent or treat protein energy wasting in HD patients. Possible benefits for participants include improvement in protein levels, sensation of general wellness, and improvements in appetite and calorie-protein intake. Risks for patients include nausea, vomiting, diarrhoea, aspiration and hypotension during HD treatment.

Where is the study run from? National Institute of Medical Science and Nutrition Salvador Zubirán (Mexico)

When is the study starting and how long is it expected to run for? September 2017 to February 2018

Who is funding the study? National Institute of Medical Science and Nutrition Salvador Zubirán (Mexico)

Who is the main contact? Dr María de los Ángeles Espinosa Cuevas angespinosac@gmail.com

Contact information

Type(s) Scientific

Contact name Dr María de los Ángeles Espinosa Cuevas

ORCID ID http://orcid.org/0000-0001-9153-5155

Contact details Vasco de Quiroga 15 Tlalpan 14080 Ciudad de México CDMX Mexico City Mexico 14080 + 52 (55) 54870900 ext. 7876 angespinosac@gmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Study information

Scientific Title

Effectiveness and safety of the intradialytic oral nutrition over nutritional markers and intradialytic hypotension in comparison with home complementation in patients undergoing hemodialysis: a noninferiority equivalence randomized trial

Study objectives

Patients undergoing hemodialysis (HD) are in risk for developing Protein Energy Wasting (PEW) which increases risk for morbidity and mortality. PEW has many components in which energy consumption is crucial. Intradialytic supplementation is an effective anabolic strategy for improving albumin, prealbulmin and protein homeostasis. Despite these effective outcomes, health personnel perceive intradialytic supplementation as a risk for intradialytic hypotension and other gastrointestinal complications.

Study hypotheses:

 Muscular strength, energy consumption and phase angle will increase at least 10% of their basal value after 3 months of intervention with a specific renal supplement.
 There won't be more than 10% on the increase of the presence of intradialytic hypotension after intervention.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics and investigation committee from Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, 12/06/2017, ref: 2231

Study design

Randomized controlled clinical trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Hemodialysis

Interventions

Simple random allocation according to shift-day treatment for hemodialysis (HD) session. Both groups will consume a liquid renal specific supplement which grants 19 grams of protein and 434 Kcal per 237 ml:

1. The intervention group will consume 120 ml at minutes 60-75 and 210-225 of a hemodialysis session.

2. The control group will consume two portions of 120 ml at home on a specific schedule on a non-HD day.

Intervention Type

Supplement

Primary outcome measure

Incidence of intradialytic hypotension, obtained from the nurse sheet at 60, 90, 120, 150, 180, 210, 240 minutes of HD sessions

Secondary outcome measures

1. Sleep quality, analysed using Pittsburgh scale applied by a trained professional at the beginning and at the end of the intervention

 Muscle strength, analysed using a dynamometer, requesting patients to press it as hard as they can after HD treatment. The measurement will be registered for 3 times on each arm
 Calorie-protein intake, measured with a 3-day dietary register. Each patient will register their food consumption during 3 days: 1) HD day, 2) No HD session weekday and 3) Weekend day. Data will be analyzed by dietary software

4. Phase angle, determined with multifrequency BIA device after HD session

5. Incidence of nausea, vomiting, cramps, obtained from the nurse sheet (present/absent) at 60, 90, 120, 150, 180, 210, 240 minutes of HD sessions

Overall study start date

01/09/2017

Completion date 01/03/2019

Eligibility

Key inclusion criteria

- 1. Chronic hemodialysis (> 3 months)
- 2. Program of 3 sessions per week
- 3. Adults aged 18-65
- 4. Kt/V > 1.2 or URR > 65%
- 5. Agree to participate and informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit 18 Years

Upper age limit 65 Years

Sex Both

Target number of participants 70

Key exclusion criteria
1. Amputee of any extremity
2. Renal transplant within 3 next months
3. HD as treatment for kidney injury
4. Hospitalization at least one month prior to the initiation of the study

Date of first enrolment 28/11/2017

Date of final enrolment 30/12/2018

Locations

Countries of recruitment Mexico

Study participating centre National Institute of Medical Science and Nutrition Salvador Zubirán Vasco de Quiroga 15 Tlalpan 14080 Ciudad de México CDMX Mexico City Mexico 14080

Sponsor information

Sponsor details

Vasco de Quiroga no. 15 Mexico City Mexico 14080 +52 (55) 54870900 ext. 7876 sam_ra89@hotmail.com

Sponsor type Research organisation

ROR https://ror.org/00xgvev73

Funder(s)

Funder type Research organisation

Funder Name National Institute of Medical Science and Nutrition Salvador Zubirán

Funder Name Abbott Laboratories (Mexico)

Results and Publications

Publication and dissemination plan

The trialists don't have an exact date for publishing the results but they want it to be within 6 months of the overall trial end date. Also, they want it to be presented on the next international congress of the international society of renal nutrition and metabolism (Genova, Italy) as an oral or poster presentation and published in a high-impact peer reviewed journal.

Intention to publish date

01/08/2018

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr. María de los Ángeles Espinosa Cuevas (angespinosac@gmail.com).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		20/03/2020	20/03/2020	No	No
<u>Results article</u>		22/07/2022	09/08/2022	Yes	No